Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6642670 | 0.89 | TAS1R3 (0.45) | ROCK2ROCK1MEN1KMT2APOLB | |
| SCHEMBL5095592 | 0.83 | MEN1 (0.78) | ROCK2MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL6638737 | 0.82 | KDM4E (0.65) | ROCK2MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL6638447 | 0.78 | MEN1 (0.52) | ROCK2ROCK1MEN1KMT2APOLB | |
| SCHEMBL6636659 | 0.78 | KMT2A (0.60) | ROCK2ROCK1MEN1KMT2APOLB | |
| SCHEMBL6637106 | 0.75 | KMT2A (0.68) | MEN1KMT2APOLBALDH1A1GAA | |
| Acetic Acid SCHEMBL2779550 | 0.74 | MEN1 (0.60) | MEN1KMT2AALDH1A1HPGDLMNA | |
| SCHEMBL4629834 | 0.74 | KMT2A (0.60) | MEN1KMT2AALDH1A1HPGDGAA | |
| SCHEMBL6637577 | 0.73 | NPC1 (0.54) | ROCK2POLBMAPK1ALDH1A1NAMPT | |
| SCHEMBL13198123 | 0.73 | ROCK2 (0.53) | ROCK2ROCK1MEN1KMT2ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984967-B1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | IAF BIOCHEM INT (CA) | 2004-02-25 | — | — | EP | claimed |
| EP-1037633-B1 | ANTIVIRAL COMPOUNDS | IAF BIOCHEM INT (CA) | 2003-09-10 | — | — | EP | claimed |
| US-20010031765-A1 | Antiviral compounds | BIOCHEM PHARMA INC. | 2001-10-18 | — | — | US | claimed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | claimed |
| EP-1037633-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC (CA) | 2000-09-27 | — | — | EP | claimed |
| WO-1999029318-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC. (CA) | 1999-06-17 | — | — | WO | claimed |
| EP-0984967-B1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | IAF BIOCHEM INT (CA) | 2004-02-25 | — | — | EP | disclosed |
| EP-1037633-B1 | ANTIVIRAL COMPOUNDS | IAF BIOCHEM INT (CA) | 2003-09-10 | — | — | EP | disclosed |
| US-6534520-B2 | Antiviral compounds | BIOCHEM PHARMA INC. (CA) | 2003-03-18 | — | — | US | disclosed |
| US-20010031765-A1 | Antiviral compounds | BIOCHEM PHARMA INC. | 2001-10-18 | — | — | US | disclosed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | disclosed |
| EP-1037633-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC (CA) | 2000-09-27 | — | — | EP | disclosed |
| EP-0984967-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC (CA) | 2000-03-15 | — | — | EP | disclosed |
| US-5945431-A | VIRICIDE | BIOCHEM THERAPEUTICS INCORPORATED (CA) | 1999-08-31 | — | — | US | disclosed |
| WO-1999029318-A1 | ANTIVIRAL COMPOUNDS | BIOCHEM PHARMA INC. (CA) | 1999-06-17 | — | — | WO | disclosed |
| WO-1997034894-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC. (CA) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031765-A1 | Antiviral compounds | ZC3HAV1, IFNAR1, EIF2AK2 | ROCK2 3500/4885ROCK1 2182/4885MEN1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.